Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Overview

Journal In Vivo

Specialty Oncology

Date 2020 Sep 3

PMID 32871796

Citations 6

Authors

Chihiro Fushimi

Daisuke Baba

Tatsuo Masubuchi

Morio Yamazaki

Yosuke Kitani

Tatsuya Kitajima

Junpei Tanaka

Kenji Hanyu

Naruhisa Tanaka

Kouki Miura

Yuichiro Tada

Affiliations

Soon will be listed here.

Abstract

Background/aim: Head and neck cancers account for 8% of all cancer cases worldwide. However, identifying the optimal treatment for recurrent or metastatic head and neck cancer (R/MHNSCC) has been challenging. The aim of this study was to evaluate the efficacy, safety, and prognostic factors of the outcome of patients with R/MHNSCC who were treated with weekly cetuximab and paclitaxel (Cmab-PTX).

Patients And Methods: The records of R/MHNSCC patients who were treated with Cmab-PTX in our institution between June 2013 and September 2017 were collected. We analyzed Overall survival (OS), progression-free survival (PFS), prognostic factors and adverse events.

Results: The records of 59 patients treated with Cmab-PTX were analyzed. The median PFS was 5.7 months, and the median OS was 11.8 months. Patients who had been administered cetuximab previously had shorter PFS and OS than those who had not.

Conclusion: Cmab-PTX may be considered as a treatment option in head and neck R/MHNSCC patients.

Citing Articles

Efficacy of Paclitaxel and Cetuximab in Recurrent/Metastatic Oral Cancer Cases Following Superselective Intraarterial Chemoradiotherapy: A Retrospective Cohort Study.

Sakuma K, Kii T, Machida T, Kikuchi Y, Yoda M, Toya S Cancer Diagn Progn. 2024; 4(6):769-774.

PMID: 39502613 PMC: 11534039. DOI: 10.21873/cdp.10394.

Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors.

Sakai A, Ebisumoto K, Iijima H, Yamauchi M, Teramura T, Yamazaki A Discov Oncol. 2023; 14(1):158.

PMID: 37642856 PMC: 10465419. DOI: 10.1007/s12672-023-00774-4.

Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma.

Yamauchi M, Minesaki A, Ishida T, Sato Y, Okamura S, Shuto H In Vivo. 2023; 37(3):1275-1280.

PMID: 37103108 PMC: 10188000. DOI: 10.21873/invivo.13205.

Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review.

Tamimi A, Tamimi A, Sorkheh F, Asl S, Ghafari A, Karimi A Cancer Rep (Hoboken). 2023; 6(5):e1802.

PMID: 37042307 PMC: 10172176. DOI: 10.1002/cnr2.1802.

Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Aguin S, Carral A, Iglesias L, Pena C, Molina A, Costa M Cancer Diagn Progn. 2023; 3(2):264-271.

PMID: 36875311 PMC: 9949534. DOI: 10.21873/cdp.10211.

References

Nakano K, Marshall S, Taira S, Sato Y, Tomomatsu J, Sasaki T . A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma. Oral Oncol. 2017; 73:21-26. DOI: 10.1016/j.oraloncology.2017.07.022. View

Guigay J, Tahara M, Licitra L, Keilholz U, Friesland S, Witzler P . The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions. Front Oncol. 2019; 9:668. PMC: 6712586. DOI: 10.3389/fonc.2019.00668. View

Sosa A, Grau J, Feliz L, Pereira V, Alcaraz D, Munoz-Garcia C . Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy. Eur Arch Otorhinolaryngol. 2013; 271(2):373-8. DOI: 10.1007/s00405-013-2537-6. View

Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-27. DOI: 10.1056/NEJMoa0802656. View

Noronha V, Patil V, Joshi A, Bhattacharjee A, Paul D, Dhumal S . A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers. South Asian J Cancer. 2017; 6(1):11-14. PMC: 5379885. DOI: 10.4103/2278-330X.202558. View

Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. View

Ferreira B, Redman M, Baker K, Martins R, Eaton K, Chow L . Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. Laryngoscope. 2016; 127(7):1583-1588. DOI: 10.1002/lary.26422. View

Pajares Bernad I, Martinez Trufero J, Urquizu L, Pazo Cid R, de Miguel A, Agustin M . Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors. Clin Transl Oncol. 2017; 19(6):769-776. DOI: 10.1007/s12094-016-1604-z. View

Peron J, Ceruse P, Lavergne E, Buiret G, Pham B, Chabaud S . Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Anticancer Drugs. 2012; 23(9):996-1001. DOI: 10.1097/CAD.0b013e32835507e5. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Uozumi S, Enokida T, Suzuki S, Nishizawa A, Kamata H, Okano T . Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK. Front Oncol. 2019; 8:616. PMC: 6300475. DOI: 10.3389/fonc.2018.00616. View

12.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

13.

Jimenez B, Trigo J, Pajares B, Saez M, Quero C, Navarro V . Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral Oncol. 2012; 49(2):182-5. DOI: 10.1016/j.oraloncology.2012.09.003. View

14.

Hitt R, Irigoyen A, Cortes-Funes H, Grau J, Garcia-Saenz J, Cruz-Hernandez J . Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2011; 23(4):1016-22. DOI: 10.1093/annonc/mdr367. View

15.

Argiris A, Harrington K, Tahara M, Schulten J, Chomette P, Castro A . Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Front Oncol. 2017; 7:72. PMC: 5422557. DOI: 10.3389/fonc.2017.00072. View